EP Patent

EP2075000A1 — Combination of azelastine and ciclesonide

Assigned to Cipla Ltd · Expires 2009-07-01 · 17y expired

What this patent protects

A pharmaceutical formulation which comprises azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and ciclesonide.

USPTO Abstract

A pharmaceutical formulation which comprises azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and ciclesonide.

Drugs covered by this patent

azelastine-hydrochloride (AZELASTINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP2075000A1
Jurisdiction: EP
Classification: —
Expires: 2009-07-01
Drug substance claim: No
Drug product claim: No
Assignee: Cipla Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.